Bharat K Misra, M.D.
Gastroenterologist and Research Director Encore Borland Groover Clinical Research (EBGCR)Biography
Dr. Misra was the class valedictorian in his high school and in college got the highest marks in chemistry and biology. He obtained his Bachelor of Medicine and Bachelor of Surgery degree from Gandhi Medical College in Hyderabad, India. He graduated First Class in all 13 subjects. Inspired by his elder brother, he came to the US and completed his internship, residency in internal medicine and fellowship in Gastroenterology at the Nassau University Medical Center, State University of New York at Stonybrook. He was Chief Resident for a year and was voted “Fellow of the Year” on graduation. After practicing for two years in upstate New York, he joined Borland Groover in 1997.
Dr. Misra enjoys the consultative aspects of Gastroenterology and Hepatology. His practice includes the full spectrum of endoscopy both inpatient and outpatient, diagnostic and therapeutic. Dr Misra has been actively involved in clinical research and has been a Principal Investigator of numerous clinical trials. His research interests include Fecal Microbiota Transplantation, C difficile infection, the Microbiome, obesity, GERD, colon cancer etc. He currently serves as the Medical Director of Encore Borland Groover Clinical Research (EBGCR.COM)
Dr. Misra was the Chief of Gastroenterology and Director of the Endoscopy Lab and currently serves on the Board of Directors at Memorial Hospital. He also serves on the Board of Directors at Jacksonville Center for Clinical Research.
Learn more about the data presented at Digestive Disease Week 2018 by Dr. Misra on a Microbiome therapy that induces remission in mild-to-moderate ulcerative colitis.
Participate in Current Trials
C. Difficile
H. Pylori
Erosive esophagitis
Ulcerative Colitis
1987 – 1988
Rotating Internship
Gandhi Hospital and affiliated hospitals 1989
Resident Physician, Internal Medicine
Nizams Institute of Medical Sciences 1990 – 1992
Residency, Internal Medicine
Nassau County Medical Center, State University of New York at Stony Brook 1992 – 1993
Chief Residency, Department of Medicine
Nassau County Medical Center, State University of New York at Stony Brook 1993 – 1995
Fellowship, Gastroenterology
Nassau County Medical Center, State University of New York at Stony BrookRESEARCH TRAINING:
03/01/2018 CITI Good Clinical Practice Course [exp. 2/2021]
05/10/2017 TransCelerate ICH GCP
03/25/2016 iMedidata Rave EDC Training
04/27/2015 TransCelerate ICH GCP
RESEARCH EXPERIENCE:
Principal Investigator:
2023-Present Eli Lilly I6T-MC-AMBZ, Ulcerative Colitis
2023-Present Series Therapeutics RDP001, Ulcerative Colitis
2022-Present Chugai Pharmaceutical DQB101US, Celiac Disease
2022-Present InterVenn INTE-NICE-001
2022-Present Freenome FRNM-005
2021-2023 Finch CDI-301, C-Difficile
2021-Present Phathom NERD-301, Non-Erosive Gastroesophageal Reflux Disease
2021-2023 Freenome FRNM-004 PREEMPT, Colorectal Cancer Prevention
2021-2022 Phathom NERD-201, Non-Erosive Gastroesophageal Reflux Disease
2020-2021 Phathom HP-301, H. Pylori
2020-Present Phathom EE-301, Erosive Esophagitis
2019-2021 Gilead GS-US-365-4237 FALCON, Ulcerative Colitis
2018-2021 Finch CP101-CDI-E02 PRISM Ext, C-Difficile
2018-2021 SERES-201, Ulcerative Colitis
2017-2021 Finch/Crestovo CDI-001, C-Difficile
2017-2021 SERES 012, Recurrent C-Difficile
2017-2022 SERES 013, Recurrent C-Difficile
2016 Synergy SP304203-05, IBS-C
2016 SERES-004 “ECOSPOR”, Recurrent C-Difficile
2016 SERES-005, Recurrent C-Difficile
2016 SERES-101, Ulcerative Colitis
2014 P-Monofer-IDA-01, Iron Deficiency Anemia
2014 Vibrant 179CLD, Constipation
2014 Rebiotix 2014-01, C-Difficile
Sub-Investigator:
2023-Present AstraZeneca D5244C00001 CROSSING, Eosinophilic Esophagitis
2022-Present Celldex Therapeutics CDX0159-08, Eosinophilic Esophagitis
2022-Present Allakos AK002-027, Urticaria
2022-Present GIE PR2053 PATENT-B, Bowel Stricture
2022-Present GIE PR2052 PATENT-E, Esophageal Stricture
2022-Present Hepion HEPA-CRV431-207, NASH
2022-Present Gilead GS-US-454-6075, NASH
2022-Present Kowa K-001-201, NASH
2022-Present Allakos AK002-018, Atopic Dermatitis
2022-Present Salix RNLC3131, ENCEPHALOPATHY DECOMPENSATION IN CIRRHOSIS
2022 Axcella Health AXA1125-101, Non-Cirrhotic, Non-Alcoholic Steatohepatitis and Fibrosis
2022-Present Celgene CC-93538-EE-002, Eosinophilic Esophagitis
2022-2022 Exact Science 2021-02 TENEO, Liver Cancer
2021-2023 Olympus OCA 2019-GI-03, Colorectal Polyp Clinical Decision Support Device
2021-2022 Allakos AK002-023, Eosinophilic Gastritis and/or Eosinophilic Duodenitis
2021-2022 Alnylam ALN-HSD-001, NASH
2021-Present Genfit GFT505B-319-1, Primary Biliary Cholangitis
2021-2023 Allakos AK002-021, Eosinophilic Duodenitis
2021-Present Celgene CC-93538-EE-001, Eosinophilic Esophagitis
2021-Present Arena APD334-202, Crohn’s Disease
2020-2022 Metacrine MET642-201, NASH
2020-Present Allakos AK002-016X EXT to Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
2020-2022 Neurogastrx NG101-201, Gastroparesis
2020-2021 Lucid EG-CL-102, Adenocarcinoma
2020-2021 Lucid EG-CL-101, Barrett’s Esophagus
2020-2021 Shire SHP647-303, Severe Ulcerative Colitis
2020-Present Enanta EDP305-102, NASH
2020-2023 Allakos AK002-014, Eosinophilic Esophagitis
2020-2022 Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
2020 Allakos AK002-019, Eosinophilic Gastrointestinal Diseases
2020-Present AbbVie M14-234, Ulcerative Colitis
2020-Present AbbVie M14-533, Ulcerative Colitis
2020-Present AbbVie M14-675, Ulcerative Colitis
2020-Present AbbVie M14-430, Crohn’s Disease
2020-Present AbbVie M14-431, Crohn’s Disease
2020-Present AbbVie M14-433, Crohn’s Disease
2019-2021 Braintree BLI4900-302, Colon Prep
2019-2023 Adare SP-1011-003, Eosinophilic Esophagitis
2019 Pfizer C1061011, NAFLD
2018 Intercept Pharmaceuticals, 747-304 NASH
2017 Medtronic COVSBCC0549 “BLINK”
2017-2020 Shire SHP647-302, Ulcerative Colitis
2017 Pfizer C1171002, NASH
2007 Abbott MO6-808, Crohn’s Disease
2007 Salix RFIB2001, IBS-D
2005 Alizyme ALTL1251/038/CL, IBS-C
2005 Alizyme ALTL1251/052/CL, IBS-C
2005 Alizyme ALTL1251/038/CL, IBS-C
2005 Alizyme ALTL1251/038/CL, IBS-C
2005 Alizyme ALTL1251/052/CL, IBS-C
2005 Salix RFIB2001, IBS-D
Henn MR, O’Brien EJ, Diao L, et al. A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis. Gastroenterology. 2021;160(1):115-127.e30.
The Role of a Primary Care Physician in the Management of Inflammatory Bowel Disease. “Northeast Florida Medicine”, 2016.
Author of Chapter on Gastrointestinal Bleeding in the Manual of Critical Care Medicine, a multi author textbook published by the American College of Physicians (ACP)
ABSTRACTS
CP101, an Investigational Orally Administered Microbiome Therapeutic was Effective for Prevention of Recurrent C. difficile Infection: Results from Open-Label PRISM-EXT Trial. DDW May 2022
CP101, an Investigational Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection: A Combined Analysis of the PRISM3 (randomized placebo-controlled) and PRISM-EXT (open-label extension) trials. DDW May 2022
CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results from a Randomized, Placebo-Controlled Trial. ACG 2021
Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection. ACG 2021
CP101 Engraftment Drives Efficacy: Results from a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection. ACG 2021
SERES-101: A multiple dose phase 1b study to evaluate the efficacy, safety and microbiome dynamics of Seres-287 in subjects with mild-to-moderate Ulcerative Colitis (UC). ACG 2021
A multiple dose phase 1b study to evaluate the efficacy, safety and microbiome dynamics of Seres-287 in subjects with mild-to-moderate Ulcerative Colitis (UC). Abstract and Oral presentation at Digestive Diseases Week in Washington D.C. June 2018
Evaluation of health related quality of life in patients treated with RBX2660 (microbiota suspension) for recurrent C. difficile infection. Bharat K. Misra, M.D., Mayur S. Ramesh, MD, Mary Kay Sobcinski, RN, MHA. Borland Groover, Jacksonville FL; Henry Ford Health System, Detroit, MI; Rebiotix Inc., Roseville MN. ACG Philadelphia, Oct 2014
RBX2660 (microbiota suspension) for recurrent C difficile infection: 60 day interim analysis of the PUNCH CD phase 2 safety study. Mayur S Ramesh, MD, Bharat Misra, MD, Arnab Ray, MD, Robert Smith, MD, Mary Kay Sobcinski, RN,MHA
Henry Ford Hospital System, Detroit, MI; Borland Groover, Jacksonville FL; Ochsner Clinic, New Orleans, LA; Rebiotix Inc., Roseville MN. Philadelphia, Oct 2014
Budd-Chiari syndrome secondary to inferior venacava thrombosis in the setting of HIV Disease and Protein C deficiency: Bharat K. Misra, M.D. Abstract and poster, American College of Physicians, New York, NY.
Endoscopic treatment of Symptomatic Intraluminal migrated Marlex mesh in banded Roux-n-Y Gastric Bypass. H. Yasrebi, B.K. Misra. Abstract and Poster presentation at the American Society for Metabolic and Bariatric Surgery (ASMBS) meeting, Washington D.C. June 2009.